Clinical Trial

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

Study acronym: TRAIN-2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2013-11-21; most recent amendment 2024-03-28.
Status change: Recruiting → Active, Not Recruiting 2016-01-21
Status change: Not Yet Recruiting → Recruiting 2013-12-11
Trial Details
NCT Number NCT01996267
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Roche Pharma AG, Borstkanker Onderzoek Groep
Conditions Breast Cancer, HER2 Positive
Enrollment 437 participants
Start Date 2013-12
Primary Completion 2018-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-29